Sorrento Therapeutics Inc... (SRNE)
0.00
-0.00 (-100.00%)
At close: Apr 03, 2025, 3:33 PM
-100.00% (1D)
| Bid | n/a |
| Market Cap | 551.28K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 10,710 |
| Avg. Volume (20D) | 71,110 |
| Open | 0.00 |
| Previous Close | 0.00 |
| Day's Range | 0.00 - 0.00 |
| 52-Week Range | 0.00 - 0.08 |
| Beta | 1.49 |
About SRNE
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 19, 2007
Employees 949
Stock Exchange NASDAQ
Ticker Symbol SRNE
